CO6341514A2 - Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica - Google Patents
Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástricaInfo
- Publication number
- CO6341514A2 CO6341514A2 CO11009937A CO11009937A CO6341514A2 CO 6341514 A2 CO6341514 A2 CO 6341514A2 CO 11009937 A CO11009937 A CO 11009937A CO 11009937 A CO11009937 A CO 11009937A CO 6341514 A2 CO6341514 A2 CO 6341514A2
- Authority
- CO
- Colombia
- Prior art keywords
- agent
- gastric
- patients
- reducing
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención está dirigida a un método novedoso para reducir a variabilidad intrapaciente en un agente farmacéuticamente activo que de manera adecuada no es absorbido en el estómago, tal como formulaciones que contienen paracetamol en pacientes que tienen dismotilidad gástrica, o un método para mejorar la analgesia en un paciente diabético, o mejorar la absorción de un agente activo en un paciente con dismotilidad gástrica, dichos métodos comprenden administrar oralmente a dicho paciente que lo necesita una forma de dosificación farmacéutica que comprende un primer agente activo, carbonato de calcio, al menos un primer agente aglutinante, y al menos un agente desintegrante como componentes intragranulares en forma de un material granulado, y como un componente extragranular al menos un coloide hidrofílico, de manera opcional un segundo agente aglutinante, carbonato de calcio, un superdesintegrante, y un segundo agente activo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0813929.7A GB0813929D0 (en) | 2008-07-30 | 2008-07-30 | Novel method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6341514A2 true CO6341514A2 (es) | 2011-11-21 |
Family
ID=39747175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11009937A CO6341514A2 (es) | 2008-07-30 | 2011-01-28 | Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8604084B2 (es) |
| EP (1) | EP2309852A4 (es) |
| CN (1) | CN102170782A (es) |
| AU (1) | AU2009276664B2 (es) |
| BR (1) | BRPI0916597A2 (es) |
| CO (1) | CO6341514A2 (es) |
| GB (1) | GB0813929D0 (es) |
| MX (1) | MX2011001124A (es) |
| MY (1) | MY151230A (es) |
| NZ (1) | NZ591408A (es) |
| RU (1) | RU2517139C2 (es) |
| WO (1) | WO2010014661A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2811202A1 (en) | 2010-09-13 | 2012-03-22 | Bev-Rx, Inc. | Aqueous drug delivery system comprising off-flavor masking agent |
| JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| CN115444823B (zh) * | 2022-10-12 | 2024-02-23 | 苏州中化药品工业有限公司 | 一种含瑞巴派特颗粒及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1182049A (en) * | 1981-07-13 | 1985-02-05 | Francis J. Sterbenz | Apap antacid composition |
| US6264983B1 (en) * | 1999-09-16 | 2001-07-24 | Rhodia, Inc. | Directly compressible, ultra fine acetaminophen compositions and process for producing same |
| GB0114069D0 (en) | 2001-06-08 | 2001-08-01 | Smithkline Beecham Plc | Composition |
| JP2006510593A (ja) * | 2002-09-12 | 2006-03-30 | ザ ユニヴァーシティ オヴ シカゴ | 胃内容排出及び胃不全麻痺のモニタリング及び診断 |
| US20050108021A1 (en) | 2003-07-31 | 2005-05-19 | Greg Anderson | System and method for routing and managing service requests |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| CN101048155A (zh) * | 2004-10-28 | 2007-10-03 | 诺瓦提斯公司 | 含有对乙酰氨基酚、咖啡因和任选的阿司匹林以及用于增强吸收的碱性剂的组合物 |
| GB0607085D0 (en) * | 2006-04-07 | 2006-05-17 | Smithkline Beecham Corp | Novel compositions |
| US7863275B2 (en) * | 2006-10-30 | 2011-01-04 | The Board Of Regents Of The University Of Texas System | Uses of tetrahydrobiopterin and derivatives thereof |
-
2008
- 2008-07-30 GB GBGB0813929.7A patent/GB0813929D0/en not_active Ceased
-
2009
- 2009-07-29 WO PCT/US2009/052039 patent/WO2010014661A1/en active Application Filing
- 2009-07-29 EP EP09803517A patent/EP2309852A4/en not_active Withdrawn
- 2009-07-29 MX MX2011001124A patent/MX2011001124A/es not_active Application Discontinuation
- 2009-07-29 MY MYPI20110429 patent/MY151230A/en unknown
- 2009-07-29 NZ NZ591408A patent/NZ591408A/xx not_active IP Right Cessation
- 2009-07-29 US US13/055,477 patent/US8604084B2/en not_active Expired - Fee Related
- 2009-07-29 CN CN2009801385066A patent/CN102170782A/zh active Pending
- 2009-07-29 RU RU2011107285/15A patent/RU2517139C2/ru not_active IP Right Cessation
- 2009-07-29 BR BRPI0916597-5A patent/BRPI0916597A2/pt not_active IP Right Cessation
- 2009-07-29 AU AU2009276664A patent/AU2009276664B2/en not_active Ceased
-
2011
- 2011-01-28 CO CO11009937A patent/CO6341514A2/es not_active Application Discontinuation
-
2013
- 2013-11-06 US US14/073,038 patent/US20140066516A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0916597A2 (pt) | 2015-08-04 |
| RU2011107285A (ru) | 2012-09-10 |
| MY151230A (en) | 2014-04-30 |
| EP2309852A1 (en) | 2011-04-20 |
| US20140066516A1 (en) | 2014-03-06 |
| GB0813929D0 (en) | 2008-09-03 |
| EP2309852A4 (en) | 2011-08-24 |
| NZ591408A (en) | 2012-12-21 |
| CN102170782A (zh) | 2011-08-31 |
| AU2009276664B2 (en) | 2013-02-07 |
| MX2011001124A (es) | 2011-03-29 |
| WO2010014661A1 (en) | 2010-02-04 |
| US20110301243A1 (en) | 2011-12-08 |
| AU2009276664A1 (en) | 2010-02-04 |
| US8604084B2 (en) | 2013-12-10 |
| RU2517139C2 (ru) | 2014-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6341514A2 (es) | Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| WO2007103113A3 (en) | Dosage forms for administering combinations of drugs | |
| WO2008040534A3 (en) | Non-mucoadhesive film dosage forms | |
| AR076153A1 (es) | Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones | |
| MX2009013574A (es) | Formas de dosificacion solidas o semisolidas de liberacion modificada. | |
| WO2010045656A3 (en) | Novel sglt2 inhibitor dosage forms | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
| JP2014528474A5 (es) | ||
| BRPI0520082A2 (pt) | formas de dosagem de risedronato | |
| BR112014025206A2 (pt) | filme oral contendo pérolas de liberação entérica de opiato | |
| BRPI0719115B8 (pt) | sistema terapêutico transdérmico para administração de buprenorfina à pele | |
| ATE494889T1 (de) | Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol | |
| UY33700A (es) | ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?. | |
| CL2008000608A1 (es) | Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naltrexona, util para el tratamiento del dolor. | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| CL2007002875A1 (es) | Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales. | |
| WO2014160216A3 (en) | Dual targeting anticancer agents | |
| BR112013011942A2 (pt) | formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida. | |
| BRPI0520797B8 (pt) | forma de dosagem farmacêutica comprimida em bicamadas | |
| BRPI0607172A2 (pt) | método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos | |
| JP2007119497A5 (es) | ||
| CL2008000607A1 (es) | Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y nalmefeno, util para el tratamiento del dolor. | |
| BR112012014107B8 (pt) | sistema terapêutico transdérmico (tts) e processo de produção de tts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |